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As human papillomavirus-like particles (HPV-VLP) represent a promising vaccine delivery vehicle, delineation of the interaction of VLP
with professional APC should improve vaccine development. Differences in the capacity of VLP to signal dendritic cells (DC) and Langerhans
cells (LC) have been demonstrated, and evidence has been presented for both clathrin-coated pits and proteoglycans (PG) in the uptake
pathway of VLP into epithelial cells. Therefore, we compared HPV-VLP uptake mechanisms in human monocyte-derived DC and LC, and
their ability to cross-present HPV VLP-associated antigen in the MHC class I pathway. DC and LC each took up virus-like particles (VLP).
DC uptake of and signalling by VLP was inhibited by amiloride or cytochalasin D (CCD), but not by filipin treatment, and was blocked by
several sulfated and non-sulfated polysaccharides and anti-CD16. In contrast, LC uptake was inhibited only by filipin, and VLP in LC were
associated with caveolin, langerin, and CD1a. These data suggest fundamentally different routes of VLP uptake by DC and LC. Despite these
differences, VLP taken up by DC and LC were each able to prime naive CD8+ T cells and induce cytolytic effector T cells in vitro.
D 2004 Elsevier Inc. All rights reserved.Keywords: Dendritic cells; Human papillomavirus like particle; T cells
Introduction monocyte-derived DC but not LC generated from peripheralDendritic cells (DC) and Langerhans cells (LC) play a
crucial role in priming MHC class I restricted T cell
responses as they are the only APCs that are capable of
stimulating resting, naive T lymphocytes and hence initiat-
ing CTL immune responses in vivo. Papillomavirus virus
like particles (PV-VLPs) are the basis of vaccines to prevent
PV infection and are immunogenic in humans with or
without adjuvant, suggesting that they have innate capacity
to activate professional APCs. As PV-VLPs represent a
promising vaccine delivery vehicle, delineation of the inter-
action of VLP with professional APC should improve
vaccine development. Previously, human papillomavirus
like particles (HPV-VLPs) have been shown to activate0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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(Fausch et al., 2002, 2003). It has been suggested that lack
of presentation of HPV-VLP-associated epitopes by LC in
the absence of CD40 signalling might define an immuno-
logical escape mechanism used by HPV during natural HPV
infection (Fausch et al., 2002, 2003).
Clathrin-mediated endocytosis is the main pathway for
internalization of extracellular material in most cell types.
DCs ingest antigens by phagocytosis, macropinocytosis, and
receptor-mediated endocytosis. Macropinocytosis samples
antigen in the fluid phase and enables antigens to be endo-
cytosed independently of the requirement for specific recep-
tors (Norbury et al., 1997; Sallusto et al., 1995). Clathrin-
independent pathways, especially endocytosis via caveolae,
may also be involved in the internalization of membrane
components (glycosphingolipids and glycosylphosphatidyli-
nositol-anchored proteins), extracellular ligands such as folic
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including Simian virus 40 (SV40), polyoma virus, echovirus
1, respiratory syncytial virus, and HIV (Gilbert et al., 2003;
Llano et al., 2002; Marjomaki et al., 2002; Werling et al.,
1999). For example, SV40 uses MHC class I as a receptor
and is internalized by caveolae. The uptake of these virus
particles by caveolae could trigger signal transduction in
endothelial cells, and viral particles were transported sub-
sequently to the endoplasmic reticulum, thus bypassing
other organelles (Norkin et al., 2002; Pelkmans et al.,
2002). HPV VLP uptake into human DC and the murine
C127 cell line has been demonstrated to occur through a
clathrin-dependent pathway. Furthermore, interaction with
heparan sulfate (HS) as an initial step in virus binding to
host cells has been described for entry of various viruses,
including HPV, into various cells (Joyce et al., 1999).
Heparin has been shown to inhibit binding of VLP to
epithelial cells through altered charge interactions with
glycosaminoglycan receptors (Joyce et al., 1999). Given
the previously demonstrated differences in the capacity of
VLP to signal DC and LC, and evidence for both clathrin
coated pits and HS in the uptake pathway of VLP into
epithelial cells, we compared HPV-VLP uptake mecha-
nisms in human monocyte-derived DC and LC, and their
ability to cross-present HPV VLP-associated antigen in the
MHC class I pathway. While VLP uptake mechanisms
differ in DC and LC, we show that both APC are able to
cross-present VLP-associated antigen to CD8+ T cells.Fig. 1. Uptake of VLP by DC and LC. LCs or DCs were pulsed for 1 h at
37 jC with HPV 6bL1 VLP, either untreated or labeled with CFDA. To
visualize unlabeled VLP, permeabilized cells were incubated with HPV
6bL1 mAb (B10.5) or control antibody, and then with biotinylated rabbit
anti-mouse antibody and streptavidin-FITC. Fluorescence was (A) detected
by flow cytometry and (B) localized by confocal microscopy. (C) The
uptake of VLP by DC and LC generated for varying periods of time in the
presence of GM-CSF, IL-4 F TGF-h1 was investigated following
incubation as above with VLP-CFDA and flow cytometry. Mean DC or
LC fluorescence intensity (MFI) is shown for each time point. Error bars
represent SEM.Results
Intracellular HPV 6bL1 VLP uptake by DC and LC
Binding of particulate antigen to receptors on DC or LC
may initiate signal transduction, resulting in cellular activa-
tion. We wished to study the interaction of virus particles
with DC and LC, using HPV VLP, which have been shown
to bind to the surface of both DC and LC, and with similar
efficiency (Fausch et al., 2002). We first compared the
intracellular location of VLP following uptake by mono-
cyte-derived DC (DC) and by monocyte-derived DC differ-
entiated in the presence of TGF-h1 (LC). Uptake and
location were established by flow cytometry and confocal
microscopy using CFDA-conjugated VLP or mAb B10.5-
specific for conformational epitopes on the VLPs (Chris-
tensen et al., 1994). Using either location technique, both
DC and LC took up VLP (Fig. 1). To assess the extent to
which VLP uptake was dependent on the duration of
monocyte differentiation to APC, DC and LC were exposed
to CFDA-VLP after 12–180 h of monocyte culture in the
presence of cytokines, and the intensity of intracellular
CFDA-conjugated VLP was assessed by flow cytometry 1
h later. The capacity for VLP uptake gradually increased
with increasing APC maturity, reaching a peak at 84 h (Fig.
1C), and decreased after 108 h.The means of uptake of 6bL1 VLP differs between DC
and LC
Major antigen uptake pathways used by APC include
macropinocytosis and phagocytosis, involving receptor-
mediated uptake via clathrin-coated pits, or caveolae. Cyto-
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macropinocytosis. Pretreatment of DC with either CCD or
amiloride blocked uptake of VLP. In contrast, pretreatment
of LC with CCD or amiloride had no significant effect on
uptake (Fig. 2). DC and LC were both sensitive to amiloride-
mediated inhibition of macropinocytosis, as amiloride
blocked uptake of dextran-FITC, taken up by macropinocy-
tosis and mannose receptor-mediated processes, by both DC
and LC (Fig. 2) (Sallusto et al., 1995). However, DC, but not
LC, were sensitive to the effects of CCD when taking up
dextran-FITC, most likely because CCD blocks the initial
steps of endocytosis but does not affect the recycling endo-
some pathway, active in LC (Salamero et al., 2001). Taken
together, these data support the hypothesis that macropino-
cytosis and phagocytosis mediate uptake of HPV 6bL1 VLP
by DC, but not by LC. Moreover, the lack of inhibition by
CCD suggests involvement of the recycling endosome
pathway in VLP uptake in LC.
The processing pathway of HPV 6bL1 in LC includes
langerin+ compartments
To pursue the hypothesis that VLPs traffic to the recy-
cling endosome pathway after uptake by LC, we examined
the collocation of VLP with CD1a and with langerin. CD1a
is an early endosome marker that does not traffic to late
endosomes and is part of the recycling endosome pathway,
and langerin is also shown to be associated with recycling
endosomes and Birbeck granules. All LC prepared from PBFig. 2. HPV 6bL1 VLP uptake by DC and LC is different. (A) DC or LC were pre
10 Ag/ml) for 30 min 37 jC before exposure to CDFA-VLPs (A) or dextran-FITC c
cells from three donors.monocytes expressed CD1a. Although the intensity of
langerin expression varied from low to high, approximately
95% of LC and only rare DCs expressed langerin (Fig. 3A).
Co-localization of CD1a and langerin with VLP was ob-
served. Both langerinhi and langerinlo LCs took up VLP.
Confocal microscopy indicated that VLPs were co-localized
to the same compartment as CD1a and langerin, in langerin+
LC (Figs. 3B and C).
Caveolae are associated with the recycling endosomal
compartment. To further assess the association of caveolae
with VLP uptake, expression of caveolin-1 by DC and LC
was first examined. By immunofluorescence microscopy,
caveolin-1 was identified in a vesicular pattern within DC
and LC, and within permeabilized cells by flow cytometry
(Fig. 4A and data not shown). Although VLPs were
predominantly distributed within endosomes, some co-lo-
calized with caveolin-1 in DC and LC (Fig. 4A). The effect
of filipin, which destroys caveolar structures, on VLP
uptake was therefore examined. Filipin had no significant
inhibitory effect on HPV 6bL1 VLP uptake by DC but
did block uptake of the positive control cholera toxin-
Alexa Red by DC and LC, indicating that caveolae were
functional (Figs. 4B and C) (Nichols, 2002). In contrast,
VLP uptake was significantly blocked by filipin pretreat-
ment of LC, confirming a role for caveolin-mediated
uptake of VLP by LC, but not DC. Lack of involvement
of caveolae in VLP uptake by DC resembles the
response of C127 cells to bovine papillomavirus particles
(Day et al., 2003).incubated with either amiloride (5 or 20 mM) or cytochalasin D (CCD, 2 or
ontrol (B). VLP uptake is shown as mean fluorescence intensityF SEM for
Fig. 3. Co-localization of 6bL1-CFDA, langerin, and CD1a within LC. LCs were incubated with 6bL1 VLP-CFDA for 1 h at 37 jC. After fixation and
permeabilization, cells were (A) incubated with mouse antihuman langerin, then biotinylated anti-mouse Ig and streptavidin-PE, and subjected to flow
cytometry. Cells stained with control mAb alone are shown in the top panel. DCs were stained with langerin (solid line) or control (dotted line) mAb only. (B)
Permeabilized cells were stained with mouse antihuman langerin mAb, then biotinylated anti-mouse Ig and streptavidin-Texas Red for confocal microscopy.
(C) LCs were exposed to HPV 6bL1 VLP-CFDA for 30 min, washed, and held for 1 h at 37 jC. Cells were fixed, permeabilized, and incubated with anti-CD1a
lyzed by confocal microscopy (C).
M. Yan et al. / Virology 324 (2004) 297–310300Polysaccharides are associated with HPV 6bL1 VLP uptake
by DC but not by LC
Surface heparan sulfate is required for the uptake of
HPV 16, HPV 11, and HPV 6b VLPs by a range of cell
types (Giroglou et al., 2001; Joyce et al., 1999). To study
followed by biotinylated anti-mouse Ig and streptavidin-Texas-Red, and anathe effect of heparin on HPV 6bL1 VLP entry to LC and
DC, VLPs were mixed with various concentrations of the
sulfated polysaccharides high molecular weight (HMW)
heparin and fucoidin, or a non-sulfated polysaccharide,
mannan, before incubation with DC or LC. Both heparin
and fucoidin could block more than 70% of VLP uptake by
Fig. 4. HPVVLP associate with caveolae. (A) DC and LCwere exposed to HPV 6bL1VLP, fixed and permeabilized, incubated with rabbit antihuman caveolin-1
polyclonal antibody, biotinylated anti-rabbit Ig, and streptavidin-Texas Red, then with HPV 6bL1 mAb (B10.5), and finally with biotinylated rabbit anti-mouse
antibody and streptavidin-FITC, then analyzed by immunofluorescence microscopy. Original magnification is 400. (B) DC and LC were preincubated with
various concentrations of filipin for 15 min, then exposed to CDFA-VLP. VLP uptake was assessed by flow cytometry. Data show the meanF SEM of the percent
inhibition by filipin of uptake of VLP by three donors. (C) DC and LCwere preincubated with either 10 Ag/ml filipin or no inhibitor and then with 0.5 Ag/ml Alexa
Red-labeled cholera toxin for 30 min. Red fluorescence of control cells treated with filipin alone (purple histogram), cells treated with cholera toxin alone (dotted
line), and cells treated with filipin followed by cholera toxin (solid green line) is shown for DC and LC, with percent inhibition indicated on each plot.
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At higher concentrations, mannan blocked about 40% of
HPV 6bL1 VLP uptake by DC but did not block LC uptake.
Titration of heparin showed that 1000 U was sufficient to
block uptake of VLP by DC, but had little or no effect on
uptake by LC in the presence of TGF-h1 (Figs. 5A and C).
The data indicate that some sulfated polysaccharides are
sufficient to prevent uptake of HPV 6bL1 VLP by DC, and
there may be an additional contribution by non-sulfated
polysaccharides. In contrast, while a proportion of DC andLC both expressed cell surface heparan sulfate as detected
by anti-syndecan-1 mAb (Fig. 5B), neither heparan sulfate
nor heparinase, which cleaves heparan sulfate (HS) from the
cell surface, affected the uptake of VLP by DC or LC (Fig.
5A). Thus, the mechanism of VLP uptake by DC appears to
be distinct from the cell surface HS-dependent mechanism
utilized by epithelial cells (Joyce et al., 1999), as uptake of
VLP by DC is not blocked by heparinase, and LC uptake of
VLP is not blocked by polysaccharides in the presence
of TGF-h1.
Fig. 5. Polysaccharides are associated with HPV 6bL1 VLP uptake by DC, but not by LC. (A) DCs or LCs were pretreated with heparinase I (3 U/ml) for 30
min at 37 jC and then exposed to VLPs. Alternatively, HMW heparin (1000 or 2500 U) or heparin sulfate (HS, 5 Ag/ml) was mixed with VLP, and DC or LC
exposed to the treated VLP. Data represent the mean F SEM percent inhibition of VLP uptake in the presence of the shown inhibitor, for LC or DC from three
donors. (B) DCs or LCs were stained with rat antihuman Syndecan-1 (solid line) or isotype control mAb (dotted line), followed by biotinylated goat anti-rat Ig,
and then streptavidin-FITC. (C) Inhibition of VLP uptake by sulfated or non-sulfated polysaccharides. DCs or LCs were incubated with different concentrations
of heparin, fucoidin, or mannan for 15 min at 37 jC before addition of HPV 6bL1 VLP-CFDA. After 1-h incubation, cells were washed and analyzed by flow
cytometry. Data represent the mean F SEM percent inhibition of VLP uptake in the presence of the shown inhibitor, for LC or DC from three donors.
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uptake of 6bL1 VLP by DC but not by LC
A number of antigen recognition molecules are defined
on the surface of APC. High expression of MMR is found
on DC and lower expression on LC (Turville et al., 2002).
CD16 is expressed by some DC, but not by LC, and ligation
of CD16 may be associated with signalling of NFnB
(Pengal et al., 2003). DC-associated, HS proteoglycan-
dependent integrin ligand (DC-HIL) (Shikano et al.,
2001b) is expressed at low levels intracellularly by DC,
but not by LC (Fig. 6B). Because the mechanism of VLP
uptake by DC appears to be distinct from cell surface HS,
we attempted to define any role for these receptors in the
uptake of VLP by DC. Anti-CD16 mAb and anti-MMR
blocked about 20% and 40% of VLP uptake by DC,
respectively, whereas antibody to the control membrane
antigen a-6 integrin or control Ig had no consistent effect.
In contrast, anti-MMR mAb blocked uptake of HPV 6bL1
VLP by LC to a lesser extent, about 20%, commensurate
with the lower levels of MMR expression by LC. To
determine whether DC-HIL plays a role in the uptake of
HPV 6bL1 VLP by DC or LC, a DC-HIL-Fc fusion protein
was used to block the uptake of VLP. Uptake of VLP byDC, but not LC, was partially blocked (50%) by DC-HIL,
but not by a control Fc fusion protein (Fig. 6A). Apparent
stimulation of VLP uptake in DC by control-Fc was not
consistent between experiments. These data together sug-
gest that the polysaccharide receptors MMR and DC-HIL
and, albeit modestly, the FcR CD16 contribute to VLP
uptake by DC. In contrast, only the MMR polysaccharide
receptor contributes to VLP uptake by LC.
Heparin blocks RelB translocation and enhanced APC
function of DC after exposure to 6bL1 VLP
DCs, but not LCs, have been shown to be activated
after uptake of HPV16-VLP, leading to upregulation of co-
stimulatory molecules and cytokine production (Fausch et
al., 2002; Lenz et al., 2001). DC activation is associated
with RelB nuclear translocation and DNA binding activity
(O’Sullivan and Thomas, 2002; Thompson et al., 2002).
To determine whether blocking VLP uptake by DC via
proteoglycan (PG) receptor-mediated phagocytosis would
block DC activation, DCs were pretreated with heparin or
with CCD before incubation with VLP. Cell surface
activation markers and binding of DNA to RelB were
assessed. As neither cell surface marker upregulation nor
Fig. 6. Uptake of VLP by candidate HPV receptors on DC and LC. (A) DC and LC were incubated with potential inhibitors of VLP cellular receptors,
including antihuman CD16 mAb, antihuman-mannose receptor (MMR) mAb, anti-a-6 integrin, and DC-HIL-Fc fusion protein, or with appropriate control
antibodies (mIg, control Fc), washed, and pulsed with HPV 6bL1 VLP-CFDA. After 1-h incubation, cells were washed and analyzed by flow cytometry.
Data represent mean inhibition of VLP uptake by DC or LC in the presence of the shown inhibitor. (B) Expression of CD16, MMR, and DC-HIL by DC and
LC. DC or LC were incubated with mouse isotype control Ig (filled histogram), antihuman CD16, or antihuman MMR mAb (open histogram) and then
analyzed by flow cytometry. For the detection of DC-HIL, DCs or LCs were fixed and permeabilized and incubated with control-Fc (filled histogram) or
DC-HIL-Fc (open histogram). Expression was analyzed in each case by flow cytometry. Representative of three experiments (*P < 0.05 compared with
control-Fc).
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the data presented here are for DC only. Heparin blocked
the enhanced expression of CD86 and CD83 induced by
VLP (Fig. 7A). Furthermore, heparin and CCD, but not
anti-CD16—consistent with its modest capacity to blockVLP uptake—blocked RelB DNA binding and cellular
activation (Fig. 7B). The data are consistent with the
hypothesis that a proteoglycan receptor-mediated phago-
cytic pathway conveys the signalling by VLP to DC for
RelB activation.
Fig. 7. Inhibition of receptor-mediated phagocytosis of VLP by DC inhibits DC function. (A) DCs or LCs were pulsed with VLP, with or without heparin, for
24 h at 37 jC, and expression of HLA-DR, CD83, and CD86 was determined by flow cytometry. *P < 0.05 compared with control DC. (B) DCs were
preincubated with inhibitors of VLP binding as shown, washed, and then exposed to HPV 6bL1 VLP in the presence or absence of 1000 U/ml HMW heparin.
RelB-DNA binding, as a measure of DC activation, was detected in nuclear extracts by ELISA. Data represent the mean F SEM of duplicate analyses. *P <
0.05 compared to control DC.
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The difference between DC and LC in the uptake and
traffic of VLP and in cellular activation in response to VLP
might indicate differences in their capacity for cross-pre-
sentation of the VLP antigen. Previously in vitro-generated
DC and LC have been demonstrated to have equivalent
capacity for T cell priming (Caux et al., 1997; Geissmann et
al., 1999). Therefore, we examined the capacity of DC and
LC to cross-prime naive CD8+ T cells to a VLP-associated
MHC class I-restricted antigenic epitope and to cross-
present the VLP antigen to primed CD8+ T cell lines. We
utilized VLP chimeric for the HLA B8-restricted FLR
peptide of EBNA1 (Burrows et al., 1992a, 1992b). Naive
CD8+ T cells from EBV seronegative donors were primed in
vitro by DC or LC, previously loaded with chimeric 6bL1-
FLR VLP. After restimulation in vitro, the function and
specificity of T cell lines cross-primed by VLP-loaded DC
or LC were evaluated. T cells primed by HPV 6bL1-FLR
VLP-loaded DC produced IFN-g in response to FLR
peptide, but not to irrelevant peptide GB906. T cells primed
by HPV 6bL1-FLR VLP-loaded LC also produced IFN-g,but required a higher concentration of peptide for activation
(Figs. 8A and B). DC-primed CD8+ T cells demonstrated
more nonspecific lytic activity than LC-primed CD8+ T
cells. CTL activity was further assayed using the HLA B8+
B lymphoma cell line BL30A pulsed with either FLR
peptide or irrelevant peptide GB906 as targets. BL30A
incubated with FLR peptide, but not GF906, was lysed by
T cell lines initially cross-primed by either DC or LC loaded
with HPV 6bL1-FLR VLP (Figs. 8C and D). In general,
FLR-specific killing relative to the background nonspecific
lytic activity of both T cell lines was low. However, both DC
and LC loaded with HPV VLP-FLR could effectively
present VLP-encoded MHC class I epitope to CD8+-resting
T cells for priming.Discussion
HPV-VLPs are candidate vaccines both for the prevention
of HPV infection (Suzich et al., 1995) and as an immuno-
genic delivery system for antigen incorporated into the PV-
VLP (Kaufmann et al., 2001; Peng et al., 1998; Rudolf et al.,
Fig. 8. Cross-priming of CD8+ T cells by DC and LC loaded with chimeric VLP. HLA-B8+ CD8+ T cells were exposed over 3 weeks in vitro to DC or LC
loaded with chimeric HPV 6bL1 expressing the FLR B8-restricted CTL epitope. T cell lines generated from loaded DC (A) or LC (B) were tested by ELISPOT
for IFN-g production in response to FLR peptide or a control peptide G8906. T cell lines generated from loaded DC (C) or LC (D) were similarly tested for
CTL activity using as targets HLA B8+ B cell line BL30A loaded with either FLR or control peptide. Representative of two experiments with error bars
representing means F SEM.
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sional APC should improve vaccine development, we com-
pared the uptake mechanism of VLP by DC and LC. A
number of mechanisms have been established by which DC
can take up antigen. Macropinocytosis results in the sam-
pling of antigen in the fluid phase and enables antigens to be
endocytosed independently of the requirement for specific
receptors (Norbury et al., 1997; Sallusto et al., 1995). Uptake
via receptors that are concentrated in clathrin-coated pits
may be involved for some substances (Chuang et al., 1997).
By following the uptake of VLP-CFDA in both DC and LC,
we studied the intracellular traffic of VLP once it was taken
up by cells. Several differences in the handling of VLP by
DC and LC emerged. DC uptake of VLP was inhibited by
cytochalasin D and amiloride, indicating that uptake was
mediated by phagocytosis and the formation of clathrin-
coated pits, in keeping with previous observations using
HPV16-VLP (Fausch et al., 2003).
In contrast to DC, the uptake of VLP by LC was clathrin-
independent as cytochalasin D and amiloride had no effect
on uptake. In LC, caveolae appear to be involved, as the
uptake of HPV 6bL1 VLP was blocked in a large part by
filipin, which extracts cholesterol from caveolae, thereby
destabilizing raft architecture (Venkatesan et al., 2003).
While some co-localization of VLP and caveolin-1 oc-curred, VLPs appear to translocate rapidly through caveolae
into the recycling endosome pathway. VLP co-localized
with CD1a+ early endosomes and langerin in LC. CD1a is
included in recycling vesicles that deliver internalized
proteins back to the cell surface rather than transporting
them more deeply into the late endocytic system (Sugita et
al., 1999). Langerin, a protein implicated in Birbeck granule
biogenesis, is also predominantly found in the endosomal
recycling compartment and in Birbeck granules. It has been
shown that Langerin traffics between the plasma membrane,
the early or sorting endosomes and the ER but not to late
endosomes, and is associated with the CD1a recycling
compartment (Mc Dermott et al., 2002). Thus, VLP may
predominantly traffic in the endosomal recycling pathway in
LC. While the mechanism of MHC loading with the VLP
antigen in this compartment is not yet known, previous
studies demonstrate that influenza antigen loading of na-
scent class II may occur directly from the early endosome
under acidic conditions (Sinnathamby and Eisenlohr, 2003).
These results differ from those previously published—
perhaps due to differences in the method of blocking with
filipin or differences in uptake between HPV16L1 and HPV
6bL1 VLP (Fausch et al., 2003).
Animal cell membranes abundantly express proteoglycans
(PGs), which are made up of a protein core with one or more
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protein ligands (Rostand and Esko, 1997). Heparan sulfate
(HS) and other GAGs are included in the proteoglycans
(Rostand and Esko, 1997; Stringer and Gallagher, 1997).
Viruses in their cellular entry process exploit this anatomical
feature of the cell membrane. Interaction with HS as an initial
step in virus binding to host cells has been described for entry
of various viruses into epithelial cells during either single or
multistep virus entry processes (Liu and Thorp, 2002). DCs
have been shown to be activated after uptake of VLP, leading
to upregulation of co-stimulatory molecules and cytokine
production (Fausch et al., 2002; Lenz et al., 2001). DC
activation is associated with RelB nuclear translocation and
DNA binding activity (O’Sullivan and Thomas, 2002;
Thompson et al., 2002). In the current studies, RelB DNA
binding was inhibited by CCD and heparin, indicating that
NFnB activation by VLP is triggered through cell surface
GAG signalling and receptor-mediated phagocytosis. Hepa-
rin inhibits binding of VLP through altered charge inter-
actions with GAG receptors (Joyce et al., 1999). Such
interactions might also explain the variable increase in VLP
uptake by LC in the presence of heparin. Unexpectedly, the
DC GAG receptor for HPV VLP appears not to be HS, as in
epithelial cells, as although a proportion of DC expressed
HS, heparinase had no effect on VLP uptake. We therefore
explored the characteristics of the DC receptor for VLP. The
highly sulfated polysaccharide fucoidin also inhibited HPV
VLP uptake by DC, and the non-sulfated polysaccharide
mannan had weaker inhibitory effects on the uptake of HPV
VLP. A recent study suggested that heparin-related binding
of DC to endothelial cells was mediated by a novel receptor,
DC-associated, HS PG-dependent integrin ligand (DC-HIL).
HS ligand binding to DC-HIL is also blocked by heparin and
fucoidin (Shikano et al., 2001a). Here we show that the
soluble fusion protein DC-HIL-Fc, which could bind to the
DC-HIL extracellular domain (ECD), also has an inhibitory
effect on the uptake of HPV VLP by DC. These data suggest
that DC-HIL is a candidate receptor for the initial binding
and uptake of VLP by DC. Both HS and hyaluronan have
been shown to activate the NFnB pathway in DC via TLR4
(Karin and Ben-Neriah, 2000; Lyakh et al., 2000). DC
activation through DC-HIL has not previously been exam-
ined (Shikano et al., 2001a).
FcgRIII (CD16) was expressed by only a proportion of
DC, and blockade of CD16 had modest effects on VLP
uptake byDC. Although ligation of Fcg receptors may induce
activation of NFnB, the current expression and blocking
studies indicate that this is not the primary receptor mediating
VLP RelB-dependent signals to monocyte-derived DC
(Alonso et al., 2000). Mannose receptors have been shown
to be involved in the binding of several viruses, as well as
yeast VLP to DC and in the activation of monocyte-derived
DC (Milone and Fitzgerald-Bocarsly, 1998; Tsunetsugu-
Yokota et al., 2003). Consistent with the effects of mannan,
anti-mannose receptor mAb partially blocked the uptake of
HPV 6bL1 VLP by DC and LC. The data raise the possibilityof co-receptor function for CD16 or integrin-recognition
RGD motifs displayed by GAGs or mannose receptors with
DC-HIL (Shikano et al., 2001a). A similar situation exists for
adenovirus, in which aVh5 serves as a co-receptor, particu-
larly for infectivity of adenovirus, along with the primary
attachment receptor HS (Summerford et al., 1999). It is not
yet elucidated which receptors are responsible for the initial
binding of VLP by LC. However, we have determined at least
that CD16, a-6 integrin, and DC-HIL are not responsible
receptors, but that the MMR is partially involved in the
uptake of VLP by LC.
Previously published data suggested that after taking up
chimeric HPV16 L1-E7, DCs, but not LCs, were able to
cross-prime E7 peptide-specific CD8+ T cells. We used the
same methodology to prime CD8+ T cells with DCs or LCs
that were pulsed with chimeric HPV 6bL1-FLR. While we
could confirm the previously published data, additional dose
titration of the FLR peptide indicated that T cell lines
generated in response to LC loaded with chimeric VLP
could also respond with specific IFN-g production in
response to higher doses of peptide. In contrast to previous
studies (Fausch et al., 2002, 2003), we found that CD8+ T
cells stimulated by either LC or DC loaded with chimeric
VLP could act as FLR-specific CTL. CTL analysis indicates
that LCs cross-prime VLP-associated epitopes to resting T
cells even if not previously signalled with CD154. The most
likely explanation for the difference in results with previous
studies is that CTL assays were carried out in the current
studies over a range of effector to target ratios and peptide
concentrations rather than a single ratio or concentration,
allowing for greater sensitivity of detection of the relative
capacity of DC and LC to cross-present VLP-associated
antigens. Thus, the current data suggest that, after uptake,
processing of VLP-associated antigen by LC might be less
efficient than by DC. Nevertheless, both APC cross-present
VLP-associated antigen in vitro. Confirmation of this ca-
pacity is required in vivo.
The current studies examined the uptake by and antigen
presentation by DC and LC of HPV-L1-VLP. From these
studies, it is possible to make inferences or novel hypotheses
regarding the mechanism of action of VLP vaccines, but not
natural HPVinfection. Our results support the hypothesis that
in vivo, LC and dermal DC are both likely to cross-present
VLP antigen in draining LN after contacting and taking up
VLP vaccines injected into skin. Simultaneous cross-priming
of VLP by both DC and LC may actually be synergistic, as
DCs activated by VLP are more likely to generate CD154+ T
helper cells, which are required for full LC activation
(Geissmann et al., 1999). While LCs were not deliberately
signalled through CD40 in vitro in the current studies, it is
possible that a small proportion of CD4+ T cells in the
cultures may have been sufficient to provide help through
CD154 ligation of LC cross-priming chimeric VLP. Our data
provide a testable model for the mechanism of CTL induction
by PV-VLP in vivo. The ability of LC to take up a large
amount of VLP but not to become activated in the presence of
M. Yan et al. / Virology 324 (2004) 297–310 307TGF-h1 supports the idea that LCs may remain immature
even after uptake of VLP at epithelial sites in vivo. However,
after uptake of VLP in the skin, LCs may migrate to draining
lymph nodes where levels of TGF-h1 are reduced. This
migration could be signalled by a6-integrin following VLP
uptake into LC (Evander et al., 1997; Price et al., 1997).
Therefore, a drop in the TGF-h levels upon migration out of
the skin, coupled with CD40 signalling by lymph node CD4+
T helper cells, would allow LC to cross-present VLP-
encoded antigens to CTL precursors in the draining lymph
node. In contrast, dermal DCs appear more likely to activate
CD4+ T helper cells in response to VLP as well as to drive
local cytokine and chemokine production, leading to a
dermal inflammatory response (Lenz et al., 1993). In this
regard, DCs developing in the absence of TGF-hmay play an
extremely important role in the distinction between cross-
tolerance and cross-priming as, in the absence of CD154
derived from CD4+ helper T cells, cross-tolerance might
result (Albert et al., 2001; Sotomayor et al., 1999).Materials and methods
Generation of VLP
HPV6b-L1s were generated as described previously
(Kirnbauer et al., 1992; Park et al., 1993). The particulate
VLP band was collected after continuous cesium chloride
density gradient centrifugation and dialyzed overnight
against several changes of PBS at 4 jC. Total protein and
L1 content was estimated by 10% SDS-PAGE and anti-L1
immunoblotting and ELISA, and the presence of intact
virus particles was confirmed by electron microscopy
(Zhou et al., 1991). For the production of chimeric VLP-
FLR, a polynucleotide encoding a well-defined HLA-B8-
restricted, EBNA-3 CTL epitope FLRGRAYGL (called
FLR) (Burrows et al., 1992a) was added 3V-terminus of
the HPV 6bL1 gene by PCR using the primers (FLR
forward BamHI) 5V cgc gga tcc atg tgg cgg cct agc gac
agc 3V and (FLR reverse EcoRI) 5V ccg gaa ttc tta caa gtc
tag ccc ata cgc acg acc ccg gag aaa gcc ggc tcc cct ata tcc
act ttg taa caa 3V. PCR products were purified and ligated at
equimolar amounts to vector with T4-DNA-Ligase (BD
PharMingen, San Diego, CA). The resulting PCR product
was purified and cloned into baculovirus transfer vector
PVL1393 (BD PharMingen) via BamHI and EcoRI sites
and transformed into Escherichia coli DH a-5 cells (Life
Technology, San Diego, CA), sequenced, and transfected
into Sf9 insect cells (ATCC, Rockville MD), as previously
described (Peng et al., 1998). The presence of chimeric L1
protein in purified VLPs was confirmed by Western blot
analysis with anti-6bL1 Ab MC15 (Kulski et al., 1998), and
the structure of VLP was confirmed by electron microscopy
(EM). Endotoxin levels in VLP preparations were measured
in a Limulus-assay using a QCL-1000 Endotoxin kit
(Pierce, BA oud-Bejerland, Holland) and were in each case<10 U/ml. HPV 6bL1 VLPs were labeled with 5- and 6-
carboxyfluorescein diacetate, succinimidyl ester (CFDA-SE
Cell Tracer Kit, Molecular Probes, Eugene, OR) by mixing
89 Al PBS (pH 8.5), 10 Ag VLP (1 mg/ml), and 10 mM
CFDA-SE. Following incubation in the dark for 4 h at RT,
VLPs were subjected to dialysis against PBS overnight
(McMillan et al., 1999).
Reagents and cell culture
Human cell culture was carried out in RPMI 1640
supplemented with 2 mM L-glutamine (Trace, Biosciences,
NSW, Australia), 100 U/ml penicillin, 100 Ag/ml strepto-
mycin, 20 mM HEPES (Gibco), 1 mM sodium pyruvate,
and 10% FBS (CSL).
Generation of APC
Peripheral blood mononuclear cells (PBMCs) depleted of
T, B, and NK cells by magnetic bead separation (MACS,
Miltenyi Biotec, Auburn, CA) were used to generate mono-
cyte-derived DC and LC in vitro as previously described
(Cavanagh et al., 1998). Enriched monocyte precursors were
cultured for 1–8 days in medium supplemented with 800 U/
ml rhGM-CSF and 400 U/ml rhIL-4 (both from Schering-
Plough, Sydney, Australia). For LC, preparation was iden-
tical except that 10 ng/ml rhTGF-h1 (Life Technology) was
added every second day.
Staining of DC and LC for flow cytometric analysis
Freshly isolated DCs and LCs were incubated with
optimal concentrations of specific mAb or mouse isotype
control antibody (DAKO, Carpinteria, CA) on ice for 30 min,
washed twice, then incubated with biotinylated anti-mouse Ig
for 30 min on ice, washed twice, then finally incubated with
streptavidin-FITC or streptavidin-PE (DAKO). For intracel-
lular staining, the cells were fixed and permeabilized by
Cytofix/Cytoperm (PharMingen) before adding mAb. Anti-
6bL1 mAb (anti-HPV 6 series, L12, B10.5, N8, and C6, and
anti-HPV 11 series, D2, H5, F6, and E38 were gifts from Dr.
Neil Christensen. Milton S. Hershey Medical Center, PA)
(Christensen et al., 1994), Mouse antihuman langerin (Immu-
nex, Marseille, France), and rabbit antihuman caveolin poly-
clonal antibody (BD PharMingen, San Jose, CA) were used.
After staining, all cells were fixed with 1% paraformaldehyde
(Sigma, St. Louis, MO) and analyzed on a FACScalibur (BD
PharMingen) using a single argon laser. All cells were fixed
with 1% paraformaldehyde (Sigma) before analysis.
Staining of DC and LC for confocal and
immunofluorescence microscopy
For confocal microscopy of DC or LC after uptake of
VLP/CFDA, cells were pulsed with VLP for 1 h at 37 jC,
then washed and cytospun onto Superfrost Plus glass slides
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incubated at RT for 45 min, and finally fixed in 4%
paraformaldehyde and mounted in fluorescence mounting
medium (DAKO, Glostrup Denmark). For double staining,
freshly isolated DC and LC were pulsed with 1 Ag/ml 6bL1-
CFDAVLP as before. At different times, the cells were put
into Lab-Tek Chamber Slides (Nunc, Rochester, NY) coated
with 0.01% poly-L-Lysine (Sigma) and incubated for 10 min
at room temperature. After fixation and permeabilization
with Cytofix/Cytoperm (PharMingen), the cells were incu-
bated with optimal concentrations of anti-CD1a or anti-
Langerin or mouse isotype control antibody on ice for 30
min, washed twice, then incubated with biotinylated anti-
mouse Ig (DAKO, Carpinteria, CA) for 30 min on ice,
washed twice, and finally incubated with streptavidin-Tex-
as-Red (Amersham, Piscataway, NJ). Cells were analyzed
by confocal microscopy (LSM, Zeiss, Jena, Germany). For
double staining with caveolin-1, DC and LC were exposed
to HPV 6bL1 VLP for 1 h, fixed and permeabilized,
incubated with rabbit antihuman caveolin-1 polyclonal
antibody, biotinylated anti-rabbit Ig and streptavidin-Texas
Red, then with HPV 6bL1 mAb (B10.5), and finally with
biotinylated rabbit anti-mouse antibody and streptavidin-
FITC, then analyzed by immunofluorescence microscopy
and imaging software (Zeiss).
Uptake of VLP by DC and LC
105 DC or LC were incubated with 1 Ag/ml VLP-CFDA
for 1 h. LCs were incubated with VLP in the presence of
TGF-h1 (+TGF-h1). For blocking experiments, DC or LC
were pretreated with amiloride (Sigma), or cytochalasin D
(CCD) (Sigma) for 15–30 min, washed three times, and
then pulsed with VLP-CFDA for 1 h. For the heparin and
fucoidin blocking experiments, 1 Ag VLP-CFDAwas mixed
with heparin (David Bull Laboratories, Victoria, Australia)
or fucoidin (Sigma) before incubation with APC. For the
heparinase treatment, DC or LC were washed once with
PBS. Heparinase (forms I and II) (Sigma) was diluted in
digestion buffer (20 mM Tris–HCl, 50 mM NaCl, 4 mM
CaCl2, pH 7.5, containing 0.01% BSA) and added to cells at
a final concentration of 1 or 3 units/well at 37 jC for 1 h.
Control cells were treated with buffer without enzyme. Cells
were washed twice before incubation with VLP-CFDA. For
the antibody blocking, DC or LC were treated with 10 mg/
ml or anti-CD16 mAb (BD PharMingen), anti-mannose
receptor (CD206) mAb (BD PharMingen), or mouse isotype
control (DAKO). After washing with PBS, the cells were
incubated with 6bL1-CFDA for 10 min at 4 jC and then 1
h at 37 jC. For the detection of cell surface heparan sulfate
proteoglycan, DC or LC were stained with rat antihuman
Syndecan-1 or isotype control mAb, followed by biotiny-
lated goat anti-rat Ig and then streptavidin-FITC and ana-
lyzed by flow cytometry. In control experiments, APC were
incubated with dextran-FITC or cholera toxin Hexa-Red (a
gift from Dr. R. Parton, University of Queensland).Preparation of DC-HIL-Fc Fusion protein and its blocking
of HPV VLP uptake by DC and LC
DC-HIL-Fc consists of extracellular domain (ECD) of
DC-HIL and the Fc region of human IgG1. The cDNA of
this protein was a gift from Dr. K Ariizumi (University of
Texas Southwestern Medical Centre, USA), which was
cloned into the pSecTagB vector (pSTB-DC-HIL-Fc) (Shi-
kano et al., 2001a). The vector and control vector for Fc
fusion protein TNF-a-Fc were transfected into COS-1 cells
by lipofectamine (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. After 96 h of transfection,
the culture supernatant was harvested and immunoglobulin
fusion proteins were purified by protein A-agarose beads
(Pierce, Rockford, IL) according to the manufacturer’s
recommendations. For the blocking experiments, various
concentrations of DC-HIL-Fc or TNF-a-Fc were incubated
with DC or LC for 10 min at room temperature. The cells
were washed and then incubated with HPV 6bL1-CFDA for
10 min at 4 jC and then 1 h at 37 jC, fixed and analyzed by
flow cytometry.
Priming CD8+ T cells with DC and LC after pulsing with
chimeric 6bL1-FLR
CD8+ T cells were isolated from HLA B8+ donors by
magnetic immunodepletion using CD4, HLA-DR, CD16,
CD19, and CD56 mAb (all from BD PharMingen) and a
magnetic cell separator (MACS, Miltenyi Biotec Inc.). DC
and LC were produced from plastic adherent cells as
described. 106 DC or LC were incubated with 10 Ag
chimeric HPV 6bL1-FLR VLP for 1 h at room temperature,
washed, and mixed with 20  106 autologous freshly
isolated CD8+ PB T cells. Cells were cultured in 24-well
plates (Costar, Cambridge, MA) at 2  106 cells/well in
complete medium for 7 days at 37 jC. Restimulations after
7 and 14 days used 0.5  106 DC or LC/well loaded with 10
Ag/ml chimeric VLP. DC and LC were washed with PBS,
irradiated 25 Gy, before addition to the T cell cultures. For
restimulations, the medium was supplemented with IL-2 at
50 U/ml at 2 and 4 days after restimulation. After 28 days,
effector cells were pooled and tested for IFN-g production
by ELISPOT and cytotoxic T cell assay.
Cytotoxic T cell assay
For VLP-specific CTL activity, DC or LC pulsed with
either VLP, chimeric VLP, FLR peptide, or G8906 (a gift
from Dr. Germain Fernando, Centre for Immunology and
Cancer Research, University of Queensland, Australia), or
BL30 B lymphoma cells (a gift from Dr. Scott Burrows,
QIMR, Australia) pulsed with FLR peptide, were labeled
with Na2
51CrO4 (Perkin-Elmer, Boston, MA), washed, and
resuspended in medium. Targets (2  104) were incubated
with varying numbers of effector T cells for 4 h at 37 jC. The
supernatant was collected into Lumaplates, dried overnight,
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Australia). Specific lysis was calculated as follows: (exper-
imental release  spontaneous release)/(maximum release 
spontaneous release) 100. The SEM for all CTL assays was
less than 10% of the plotted percent-specific lysis.
ELISPOT
MultiScreen-HA plates (Millipore, Bedford, MA) were
coated with rat anti-mouse IFN-g mAb at a concentration of
10 Ag/ml in PBS at 4 jC overnight. Coated plates were then
washed six times with PBS with 0.25% Tween 20 (PBST)
and then blocked with 200 Al PBS/5% FCS for at least 3 h at
37 jC. For CD8+ T cell lines derived after T cell stimulation
with DC or LC incubated with chimeric VLP, a total of 2.0
105 cells/well was incubated in the presence or absence of
FLR peptide or irrelevant peptide (G8906) for 40 h at 37 jC.
After washing three times with PBS 0.05% Tween, biotiny-
lated antihuman IFN-g (Mabtech AB, Nacka, Sweden) was
added and incubated at room temperature for 2–4 h, followed
by streptavidin alkaline phosphatase (DAKO) for an addi-
tional 2 h. Dark spots were developed over a 30-min reaction
with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetra-
zolium (BNIP/NBT) tablets (Sigma). The spots were counted
under a dissecting microscope using video imaging software
(Vision Dynamics, Herts, United Kingdom).
Protein extraction and NF-jB binding ELISA
Nuclear and cytoplasmic extracts were prepared as pre-
viously described (O’Sullivan and Thomas, 2002), and
protein estimations carried out using a Protein Assay kit
(Bio-Rad, Hercules, CA). RelB DNA binding was detected
by ELISA using a Mercury Transfactor p50 Kit (Clontech,
Palo Alto, CA) and anti-RelB (sc-226) from Santa Cruz
Biotech (Santa Cruz, CA), as described (O’Sullivan and
Thomas, 2002). Nuclear extracts (10 Ag) were bound to
wells coated with NF-nB consensus oligonucleotide then
incubated with anti-RelB, followed by anti-rabbit HRP-
conjugated Ig. Nuclear RelB was estimated by measuring
color development at 650 nm using a Multiskan plate reader
(Labsystems, Chicago, IL).
Statistical analysis
Paired statistical analysis was performed by using the
Student’s two-tailed t test.References
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